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Background:The development of antibodies against coagulation factor VIII (fVIII) is a serious complication of hemophilia
A.
Results: Small angle x-ray scattering reveals amolecular envelope solution structure of two inhibitor antibodies bound to theC2
domain of fVIII.
Conclusion: Multiple inhibitor antibodies can bind to the fVIII C2 domain simultaneously, and modeling suggests the local-
ization of key epitopes.
Significance: Understanding fVIII-inhibitor interactions is crucial for developing more effective hemophilia A therapies.
The most significant complication for patients with severe
cases of congenital or acquiredhemophiliaA is the development
of inhibitor antibodies against coagulation factor VIII (fVIII).
The C2 domain of fVIII is a significant antigenic target of anti-
fVIII antibodies. Here, we have utilized small angle x-ray scat-
tering (SAXS) andbiochemical techniques to characterize inter-
actions between two different classes of anti-C2 domain
inhibitor antibodies and the isolated C2 domain. Multiple
assays indicated that antibodies 3E6 and G99 bind indepen-
dently to the fVIII C2 domain and can form a stable ternary
complex. SAXS-derived numerical estimates of dimensional
parameters for all studied complexes agreewith the proportions
of the constituent proteins.Ab initiomodeling of the SAXS data
results in a long kinked structure of the ternary complex, show-
ing an angle centered at the C2 domain of 130°. Guided by
biochemical data, rigid body modeling of subunits into the
molecular envelope of the ternary complex suggests that anti-
body 3E6 recognizes a C2 domain epitope consisting of the
Arg2209–Ser2216 and Leu2178–Asp2187 loops. In contrast, anti-
body G99 recognizes the C2 domain primarily through the
Pro2221–Trp2229 loop. These two epitopes are on opposing sides
of the fVIII C2 domain, are consistent with the solvent accessi-
bility in the context of the entire fVIII molecule, and provide
further structural detail regarding the pathogenic immune
response to fVIII.
Hemophilia A is an X-linked bleeding disorder that affects 1
in 5000 males worldwide and that is caused by loss of function
of blood coagulation factor VIII (fVIII),2 usually as the result of
a genetic mutation. Currently, the most effective treatment for
hemophilia A patients is fVIII replacement therapy, which
involves infusions of functional fVIII (either recombinant or
plasma-derived) (1–3). The most significant complication to
this treatment is the development of an immune response to
the infused fVIII, occurring in 30% of hemophilia patients
that receive treatment (4–7). Additionally, antibodies against
fVIII develop in the non-hemophiliac population, resulting in
acquired hemophilia A (8). Although immune tolerance induc-
tion has shown clinical success for the eradication of inhibitor
antibodies in many cases, approximately one in four patients
fail immune tolerance induction therapy (9). Additionally,
immune tolerance induction can be a prohibitively expensive
treatment due to the large quantities of fVIII required.
fVIII is a large 2332-residue glycoprotein cofactor within the
intrinsic pathway of blood coagulation. The domain architec-
ture of unprocessed fVIII is A1-A2-B-A3-C1-C2 (10, 13). The
threeAdomains form a trimeric structure homologous to ceru-
loplasmin, and the two C domains are distant homologs to the
discoidin protein fold, including galactose oxidase and lactad-
herin (14). After secretion, fVIII circulates as an A1-A2-B/A3-
C1-C2 heterodimer bound to von Willebrand factor (vWF)
(15–17). Upon proteolytic activation by either fXa or thrombin,
fVIII is converted to “activated” fVIII (fVIIIa), which forms an
A1/A2/A3-C1-C2 heterotrimer that dissociates from vWF and
binds to activated platelet surfaces (PS) via stereoselective rec-
ognition of exposed L-phosphatidylserine headgroups (12, 18).
Uponbinding PS in the presence of calcium, fVIII interactswith
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fIXa (forming the intrinsic “tenase” complex), increasing the
fIXa-catalyzed activation of fX by 200,000-fold (10–12, 19).
The immune response against therapeutic doses of plasma-
derived or recombinant fVIII results in antibody responses
wherein the majority of epitopes are found within the A2 and
C2 domains (20). Antibodies with epitopes localized to the C2
domain can inhibit the activity of fVIII by a variety of mecha-
nisms, including 1) blocking the ability of fVIII to bind vWF
and/or PS, 2) inhibiting the proteolytic activation of fVIII by
thrombin or fXa, or 3) directly inhibiting the cofactor function
of fVIIIa (21–26). fVIII inhibition behavior generally falls
within one of two distinct kinetic regimes referred to as types I
and II. Type I inhibitor antibodies obey second-order kinetics
and result in full inhibition of fVIII, whereas type II inhibitors
exhibit more complex kinetics and do not fully inactivate fVIII,
even at saturating concentrations (27).
Initial characterization of “classical” anti-C2 inhibitor anti-
bodies showed interference with the ability of fVIII to bind PS
and vWF (21, 24–26). The binding regions for PS and vWFhave
been shown to at least partially overlap, as binding to PS and
vWF is mutually exclusive (28–30). More recent studies have
described the development of “non-classical” inhibitor anti-
bodies that block the proteolytic activation of fVIII by thrombin
or fXa in both the presence and absence of vWF (22, 31). More-
over, additional studies suggest that the anti-C2 immune
response is largely dominated by non-classical inhibitors (22).
This class of anti-C2 antibodies often possesses type II kinetics
with inhibitory titers above 10,000 Bethesda units/mg of IgG
and have been shown to be pathogenic (32, 33).
The C2 domain of fVIII makes a direct contribution to the
binding of vWF and PS and is essential for the cofactor function
of fVIIIa (11, 14). Some studies also suggest a role for the C2
domain in interactions of fVIII with thrombin and fXa,
although more studies are needed to fully elaborate the details
of these proposedC2-protease interactions (31, 34, 35). Various
x-ray crystal structures of the C2 domain, accompanied by bio-
chemical data, have provided a putative model for the mecha-
nism of membrane binding by fVIII, in which surface-exposed
hydrophobic residues protruding from the ends of two -hair-
pin turns within the C2 domain embed within the nonpolar
lipid bilayer of PS (14, 36, 37). Directly above the -hairpin
turns is a ring of positively charged basic residues that plausibly
interact electrostatically with the negative charge of the phos-
phatidylserine headgroup. The 2.0 Å x-ray crystal structure of
the C2 domain bound to a classical antibody inhibitor
(BO2C11) shows that these residues are completely seques-
tered at the protein-protein interface, thereby completely
blocking the ability of fVIII to bind PS, as well as vWF (37).
To investigate the structural details of interactions between
the fVIII C2 domain and classical/non-classical inhibitor anti-
bodies, we employed small angle x-ray scattering (SAXS). The
SAXS technique has been successfully utilized for the low res-
olution structural characterization of a wide range of biomo-
lecular systems, from discrete proteins to complex assemblies
(40). Despite the low resolution limitation of SAXS, a major
advantage is that protein complexes can be analyzed in solu-
tion, under physiological conditions, with negligible perturba-
tion of native tertiary structure.
Epitope mapping studies have recently shown that various
classical and non-classical antibody pairings have discrete
binding regions, allowing for more than one antibody to bind
fVIII simultaneously (22). Here, we present the SAXS-derived
solution structure model of the fVIII C2 domain in a ternary
complex with the Fab fragments of monoclonal antibodies
(mAbs) 3E6 andG99,which have been previously characterized
as classical and non-classical antibody inhibitors, respectively
(22). Preliminary evidence suggests that the 3E6 and G99 anti-
body pair displays positive cooperativity.3 Previous descrip-
tions of antibody cooperativity have been limited to studies of
antibody-based HIV-1 vaccine studies and Fc-dependent
mechanisms (38, 39).
The SAXS-derived molecular envelope for the ternary com-
plex indicates an extended bent structure, which, along with
biochemical data, allows for modeling of epitopes on the sur-
face of the fVIII C2 domain for mAbs 3E6 and G99. To our
knowledge, this study represents the first use of SAXS for the
determination of antibody epitopes to the level of specific
exposed loops on the antigenic surface. These results contrib-
ute to the understanding of the complex pathogenic humoral
response to fVIII.
EXPERIMENTAL PROCEDURES
Wild-type and K2183A Mutant fVIII C2 Domain Expression
and Purification—The fVIII C2 domain was subcloned into an
ampicillin-resistant pET15b vector containing an N-terminal
His6 tag adjacent to a thrombin cleavage sequence as described
previously (41, 42). The introduction of the K2183A mutation
into the plasmid encoding the C2 domain was accomplished
using the QuikChange Lightning mutagenesis kit (Agilent,
Santa Clara, CA) following the manufacturer’s recommenda-
tions. Sequencing of the K2183A mutant plasmid was per-
formed by Nevada Genomics (Reno, NV). The expression con-
structs were transformed into Escherichia coli BL21(DE3) cells
and subsequently grown in LB medium in the presence of 50
g/ml ampicillin. Single colonies were used for inoculating
10-ml LB/ampicillin cultures, which were grown overnight
with shaking at 37 °C and then added to 1 liter of LB/ampicillin
and shaken at 37 °C until the absorbance at 600 nm reached a
value of 0.6–0.8. Protein growthwas induced by the addition of
isopropyl -D-thiogalactopyranoside to 500 M, and the tem-
perature was adjusted to 15 °C for overnight induction.
Following harvest by centrifugation at 8000 rpm for 10min at
4 °C (FIBERLite F10-6x500y rotor, Thermo Fisher Scientific,
Waltham, MA), cells were resuspended in lysis buffer (300 mM
NaCl, 20 mM Tris-HCl (pH 7.0), 10 mM imidazole, 0.01% (v/v)
Triton X-100, and 2.5% (v/v) glycerol), 1 mM PMSF, and 0.5–
0.8 mg/ml lysozyme for 1 h at 4 °C. Resuspended cells were
sonicated on ice using a 1/2-inch titanium horn attached to a
Branson 450 sonifier (50% duty cycle) and then clarified by cen-
trifugation at 16,000 rpm for 30 min at 4 °C (FIBERLite F21-
850y rotor, Thermo Fisher Scientific), followed by filtration
with 0.8-m cellulose sterile syringe filters. TALON-immobi-
lized cobalt affinity resin (Clontech, Mountain View, CA) was
equilibrated in lysis buffer and incubated with filtered lysate for
3 P. Lollar, personal communication.
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1 h at 4 °C. The resinwas rinsedwith lysis buffer; with 300NaCl,
20 mM Tris-HCl (pH 7.2), 10 mM imidazole, and 2.5% (v/v)
glycerol; and with the same buffer but with 150mMNaCl. His6-
tagged C2 was eluted with 150 mM NaCl, 20 mM Tris-HCl (pH
7.2), 150 mM imidazole, and 2.5% (v/v) glycerol (yield of 2.5
mg/1 liter growth).
The eluate was exchanged into storage buffer containing 50
mM NaCl and 25 mM Tris-HCl (pH 7.2) and concentrated to
1–4 mg/ml using a Mr 10,000 cutoff concentrator (Millipore).
Next, ion exchange chromatography was performed using
Macro-PrepTM strong cation exchange support (Bio-Rad). Elu-
tionwas achieved using a salt gradient from 50 to 500mMNaCl.
Eluted His6-C2 was concentrated to 6–8 mg/ml in storage
buffer (100mMNaCl and 25mMTris-HCl (pH 7.2)) and further
purified by size exclusion chromatography with a Superdex 75
column (GE Healthcare) equilibrated in storage buffer. Elution
fractions containing pure C2 (assessed by SDS-PAGE to be
95% pure) were pooled, concentrated to 5–10 mg/ml, flash-
frozen in liquid nitrogen, and stored at 80 °C. For C2 prepa-
rations to be analyzed by SAXS, the hexahistidine tag was
removed as follows. His6-C2 was mixed with 1 unit of throm-
bin/100 g of His6-C2, diluted with thrombin cleavage buffer
(50mMNaCl, 20mMTris-HCl (pH8.0), 2.5mMCaCl2, and 2.5%
(v/v) glycerol) to a final volume of 100–200 l, and incubated
overnight at 15 °C. Thrombin was removed with benzamidine-
Sepharose 6B resin (GE Healthcare), and residual His-tagged
C2 was removed via a second TALON affinity column. Finally,
cleaved C2 was purified by size exclusion chromatography,
concentrated, and stored as described above.
Antibody Production and Fab Purification—Murine anti-
fVIII C2 domain monoclonal hybridomas (3E6 and G99) were
developed as described previously (22). Large-scale antibody
production was performed by Elizabeth Wayner (Antibody
Production Facility, Fred Hutchinson Cancer Research Center,
Seattle,WA).mAbswere purified fromhybridoma supernatant
with a NAbTM Protein A Plus spin column (Thermo Scientific,
Rockford, IL) according to the manufacturer’s instructions.
The Fab fragments of 3E6- and G99-purified IgG were gener-
ated using immobilized papain (Thermo Scientific) following
the manufacturer’s cleavage protocol. Fab fragments were then
isolated from the resultant Fab/Fc mixture via secondary pas-
sage over a Protein A column and collection of the initial flow-
through. Fab fractions were purified further by size exclusion
chromatography with a Superdex 75 column in storage buffer.
Purified Fabwas concentrated to 10–20mg/ml, frozen in liquid
nitrogen, and stored at 80 °C.
Complex Preparation and Size Exclusion Chromatography
Analysis—To prepare C2-Fab complexes, a 1.5 molar excess of
the purified C2 domain was incubated with Fab fragments at
37 °C for 30 min, followed by adjustment of the sample volume
to 2ml and injection onto a Superdex 75 size exclusion column
equilibrated in storage buffer. Elution peaks corresponding to
C2-Fab complexes were collected and concentrated to 5
mg/ml. For the relative comparison of complex masses, elution
profiles of identically prepared samples consisting ofC2, Fab, or
C2-Fab complexes were employed.
C2 Domain Affinity Pulldown Assay—Human His6-C2 (50
M) was incubated with 3E6 or G99 Fab (50 M) in 100 l of
binding buffer (25 mM Tris (pH 7.2), 100 mM NaCl, and 5 mM
imidazole) for 20 min at room temperature. Samples were then
applied to 100l of equilibrated nickel-nitrilotriacetic acid (Ni-
NTA) resin for an additional 20 min with gentle rocking. Next,
the Ni-NTA resin was pelleted via centrifugation at 13,000 rpm
for 1 min, followed by removal of the supernatant, which was
stored for SDS-PAGEanalysis. The resinwas thenwashed three
times with 200 l of binding buffer by mixing, incubated for 1
min, and centrifuged at 13,000 rpm for 1 min, and the superna-
tant was removed. Finally, the resin was washed with 200 l of
elution buffer (25 mM Tris (pH 7.2), 100 mMNaCl, and 150 mM
imidazole), and the supernatant was subjected to SDS-PAGE
analysis. Control samples consisted of C2 or Fab alone.
For analysis of ternary complex formation, the same proce-
dure was employed with minor alterations. Ni-NTA-bound
His6-C2 was incubated with a mixture consisting of 3E6 Fab
and G99 IgG or, conversely, 3E6 IgG and G99 Fab. After wash-
ing the resin, sampleswere eluted and analyzed onnonreducing
SDS-polyacrylamide gels, which allowed for the unambiguous
identification of 3E6 and G99 within individual samples.
Enzyme-linked Immunosorbent Assays—All ELISA experi-
ments utilized NuncTM MaxiSorp 96-well ELISA plates
(Fisher). Incubation periodswere carried out at 37 °C for 45–60
min exceptwhere indicated, and samplewells were rinsed three
times with 150 l of TBS buffer (25 mM Tris-HCl (pH 7.4), 150
mM NaCl, and 2 mM KCl) between each incubation step.
For the measurement of C2 (WT or mutant) binding to 3E6
or G99 IgG, plates were first coated via incubation with 100 l
of 100 nM IgG in TBS buffer. Plates were then blocked by incu-
bation with 175 l of 2% BSA in TBS buffer. Next, 100 l of
His6-C2 in 1% BSA/TBS was added at the concentrations indi-
cated in the figure legends, followed by incubation for 90min at
37 °C. To bind exposed His tags, ELISA wells were then incu-
bated with 100 l of a 1:2000 dilution of HisDetectorTM Ni-
NTA-alkaline phosphatase conjugate (KPL,Gaithersburg,MD)
in 1% BSA/TBS. Finally, for colorimetric detection, 100 l of 1
mg/ml p-nitrophenyl phosphate (pNPP; MP Biomedicals,
Santa Ana, CA) in 0.1 M 2-amino-2-methyl-1,3-propanediol
(pH 10.3) was added, the reaction was allowed to proceed for
10–20 min, and well absorbances at 405 nm were read in a
BioTek Epoch plate reader. A one-site saturation binding
model was used to fit the normalized ELISA data from at least
three separate experiments, and estimates for the disassocia-
tion constants (Kd) for each interaction were calculated using
GraphPad Prism software.
For ELISA-based detection of C2–3E6 Fab-G99 IgG ternary
complex formation, amodified procedurewas employed. Plates
were first coated with 100 l of 100 nM 3E6 Fab, followed by
secondary coating with 100 nM C2 domain. After blocking, 100
l of G99 IgGwas added at varying concentrations, followed by
detection using 100 l of a 1:1000 dilution of goat anti-mouse
IgG (Invitrogen) in 1% BSA/TBS, incubation with 1 mg/ml
pNPP, and absorbance measurement as described above.
SASX Data Collection and Processing—SAXS data were col-
lected remotely at the Advanced Light Source at Lawrence
Berkeley National Laboratory (Berkeley, CA) on SIBYLS beam-
line 12.3.1. Data were collected for each sample at three differ-
ent protein concentrations with x-ray exposure times of 0.5, 1,
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and 6 s. X-ray scattering data were processed, and buffer scat-
tering was subtracted according to Advanced Light Source
beamline specifications. Scattering curves for each protein
and/or complex were merged and subsequently used for
Guinier and Kratky analyses using the program PRIMUS (43).
The maximum particle dimensions (Dmax) for each data set
were determined with Perl scripts that iteratively calculate the
real-space pairwise distance distributions (P(r)) for varying
Dmax valueswith theGNOMprogram (44, 45). Radii of gyration
(Rg) were calculatedwith default settings from both theGuinier
approximation and P(r) distributions. Ab initio modeling was
performedwith bothDAMMIF andGASBOR software (46, 47).
Fifty independent runs of each simulation were averaged
together with theDAMAVER software (48). Beadmodels of the
molecular envelopes for each structure were converted to sur-
faces with Situs and Chimera following the developers’ specifi-
cations (49, 50). Rigid bodymodeling of known structural com-
ponents (C2 domain and Fab scaffolds) into SAXS-derived
molecular envelopes was manually performed using PyMOL
(DeLano Scientific LLC).
Bethesda Assays for Inhibition of fVIII—The effect of 3E6/
G99 whole IgG or Fab on inhibition of fVIII in a one-stage
clotting assay was determined as described previously (22). Full
fVIII activity corresponded to the response of pooled normal
human plasma (George King Bio-Medical, Inc., Overland Park,
KS). The resulting inhibition curve was fitted using a four-pa-
rameter logistic equation (22).
RESULTS
The anti-fVIII inhibitor antibodies 3E6 and G99 were ini-
tially characterized in a competition ELISA study employing
full-length fVIII (22). To confirm the specificity of these anti-
bodies for the fVIII C2 domain, we first employed an affinity
capture assay using the hexahistidine-taggedC2domain as bait.
After preincubation of the C2 domain with each Fab fragment
of mAbs 3E6 and G99, the putative binary complexes were
bound to Ni-NTA-immobilized metal affinity resin, washed,
and then eluted with high concentrations of imidazole. The
resultant fractions were analyzed by SDS-PAGE (Fig. 1).
The flow-through from each incubation indicated that both the
purified C2 domain alone and each Fab fragment in the pres-
ence of the C2 domain did not immediately elute from the col-
umn. In contrast, the control samples lacking C2, composed of
both the G99 and 3E6 Fab fragments, were detected in the ini-
tial flow-through, indicating that neither Fab fragment pos-
sessed affinity for the Ni-NTA resin. Upon addition of imida-
zole, the isolated C2 domain, as well as each binary complex,
eluted as expected (Fig. 1). These results indicate that Fab frag-
ments derived from both antibodies G99 and 3E6 recognize the
C2 domain independently. Additionally, a variation of this
method provided evidence of ternary complex formation;
immobilized C2 formed stable complexes with Fab/IgG pairs
(i.e. 3E6 Fab  G99 IgG), which could be identified by nonre-
ducing SDS-PAGE via size discrimination (Fig. 2).
Size exclusion chromatography elution profiles provided fur-
ther quantification of C2-Fab complex formation (Fig. 3). An
excess of the C2 domain was incubated with 3E6 and/or G99
Fab and injected onto a Superdex 75 column.As shown in Fig. 2,
the relative elution volumes for the isolated C2 domain, each
Fab fragment, each C2-Fab binary complex, and the ternary
complex decreased, consistent with the expected increase in
molecular mass of each complex. Unexpectedly, the isolated
3E6Fab fragment exhibited a smaller retention volume than the
G99 Fab fragment, despite the near-identical masses of these
two components. Upon inspection of the SDS-polyacrylamide
gel of purified 3E6 Fab, we observed a small protein contami-
nant that co-purified with 3E6. Following formation of the
C2–3E6 Fab binary complex, however, themajority of the small
protein contamination was removed, as the elution volumes of
both binary complexes were identical. Upon analysis of the
putative ternary complex, we observed a single high molecular
mass peak at a reduced retention volume, relative to the binary
complexes, which supports the conclusion that a stable ternary
complex is formed. Finally, a peak corresponding to the isolated
C2 domain was observed for each complex due to the molar
excess of the C2 domain used in the formation of each complex
to assist in minimizing residual unbound Fab (the presence of
which could present difficulties in chromatographic separa-
tion). Upon quantification of the C2 domain present in these
excess peaks, we found equivalency between the mass of C2
collected and the molar excess of C2 added during complex
preparation, providing further validation of our preparative
techniques.
The binding of His6-C2 to immobilized 3E6 or G99 IgG was
analyzed using ELISAmethods (Fig. 4A). Upon titration of 3E6
or G99 IgG-coated wells with His6-C2 and subsequent detec-
tion of His6-C2 with the Ni-NTA-alkaline phosphatase/pNPP
system, we observed saturation binding behavior, which, upon
FIGURE 1. Formation of C2-Fab binary complexes. Shown is the stable
binding of Fab fragments to His6-C2 as measured by retention on Ni-NTA
resin. Flow-through fractions are defined as fractions unbound by resin, and
the Ni-NTA elution fractions were recovered by the addition of high imidazole
concentrations. A, C2-G99 Fab binary complex. B, C2–3E6 Fab binary complex.
Lanes 1 and 4, fVIII C2 domain; lanes 2 and 5, Fab alone; lanes 3 and 6, C2-Fab
binary complex.
FIGURE 2. Ternary complex formation. An assay similar to that described in
the legend to Fig. 1 was performed, except that samples were analyzed under
nonreducing conditions by SDS-PAGE. A, C2–3E6 IgG-G99 Fab ternary com-
plex. B, C2–3E6 Fab-G99 IgG ternary complex. Lanes 1 and 5, C2; lanes 2 and 6,
IgG and Fab alone; lanes 3 and 7, C2-Fab-IgG ternary complex; lane 4, molec-
ular mass ladder.
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fitting a classical one-site binding model, yielded apparent Kd
estimates of 3.2 0.8 nM for the C2–3E6 complex and 8.1 1.9
nM for the C2-G99 complex. The binding of His6-C2 to blocked
control wells lacking IgG was negligible (data not shown).
An additional ELISA experiment provided further evidence
for ternary complex formation. ELISA plate wells were coated
with 3E6 Fab, blocked, and then incubated with the C2 domain
to bind immobilized 3E6 Fab. Titration of these wells with G99
IgG and detection with goat anti-mouse IgG-alkaline phospha-
tase/pNPP revealed binding of G99 IgG to 3E6 Fab-immobi-
lized C2 (apparent Kd of 5 nM), indicative of ternary complex
formation (Fig. 4B). The initial coating of plates with 3E6 Fab,
instead of whole IgG, was performed to ensure that only bound
G99 IgG would be detected, as the goat anti-mouse IgG-alka-
line phosphatase conjugate used selectively recognizes the Fc
region of murine IgG, which is absent in Fab preparations. G99
IgGdid not bind towells coated onlywith 3E6 Fab or to blocked
wells that were subsequently incubated with C2. The comple-
mentary experiment, coating with G99 Fab and C2, followed by
3E6 IgG titration, did not yield the expected binding results due
to poor binding of G99 Fab to the ELISA plate wells (data not
shown).
To further characterize the solution behavior of the C2
domain and its complexes with mAbs 3E6 and G99, we
employed SAXS (Figs. 5–7). The merged scattering curves for
all proteins and complexes are shown in Fig. 5. Initial charac-
terization of the fVIII C2 domain, the 3E6 and G99 Fab frag-
ments, both binary complexes, and the C2–3E6-G99 ternary
complex indicated that each protein and/or complex was
folded (by Kratky plot analysis) (supplemental Fig. 2), and no
indication of protein aggregation was present in all samples (by
Guinier approximation analysis) (supplemental Fig. 1). Addi-
tionally, the Rg and the extrapolated intensity at zero scattering
angle (I(0) were approximated from each scattering curve
(Rgrecip) and calculated with the GNOM program (Rgreal). Both
independent determinations of Rg were consistent with each
other, as shown in Table 1. Additionally, the Dmax and P(r)
values for each complex were calculated with the GNOM pro-
gram (Fig. 6 and Table 1).
As expected, the C2 domain, 3E6 Fab, and G99 Fab each
possessed the smallest Rg values: 16.52, 27.31, and 26.93 Å,
respectively. The C2–3E6 and C2-G99 binary complexes dis-
played similar dimensions, with Rg values of 31.86 and 32.34 Å
and Dmax values of 115 and 120 Å, respectively. Finally, the
C2–3E6-G99 ternary complex possessed the largest dimen-
sions, with an Rg of 47.8 Å and a Dmax of 170 Å (Table 1). The
significantly larger dimensions for the ternary complex are con-
sistent with a long extended structure in which the C2 domain
is flanked by the two respective antibodies binding to opposing
sides.
Following GNOM calculation of P(r) functions from scatter-
ing data for each protein or complex, low resolution structural
models were calculated ab initio using the programs DAMMIF
and GASBOR. For each SAXS data set, 50 independent runs
were performed with both programs, which were subsequently
averaged with the DAMAVER program. Bead and dummy res-
idue models from the DAMMIF and GASBOR programs,
respectively, were transformed into molecular envelopes with
the programs Situs and Chimera (Fig. 7).
The ab initio molecular envelope models of the C2 domain,
each Fab fragment, and each binary complex all displayed the
dimensions expected for each protein or complex. However,
the ternary complex displayed a molecular envelope that is
elongated with an angle of 130°. Alignment of the molecular
envelopes for the C2 domain, 3E6 Fab, and G99 Fab in the
ternary complex (Fig. 7A) and alignment of the two binary com-
plexes (Fig. 7B) indicated the molecular arrangement of each
protein within the ternary structure. As shown in Fig. 7A, the
C2 domain is flanked by molecular envelopes for each of the
respective anti-Fab antibodies. Additionally, alignment of
the two binary complexes indicated an overlap of the two
molecular envelopes that coincides with the size of the C2
domain (Fig. 7B).
With the aid of prior epitope mapping data based on compe-
tition ELISAs and mutagenesis (22), structures for two proto-
typical Fabmodels (ProteinDataBank code 1IQD) aswell as the
1.5 Å x-ray crystal structure of the fVIII C2 domain (code
1D7P), were modeled as rigid bodies into the ternary complex
FIGURE 3. Size exclusion chromatography of proteins and complexes. Rel-
ative elution volumes for each protein and/or complex are overlaid with nor-
malized absorption values. Dashed lines, uncomplexed protein components
(C2 domain, G99 Fab, and 3E6 Fab); solid lines, binary and ternary protein
complexes (C2-G99 Fab binary, C2–3E6 Fab binary, and C2–3E6 Fab-G99 Fab
ternary). An excess of the fVIII C2 domain was present in each complex to
ensure saturation of Fab-binding sites.
FIGURE 4. ELISA of C2-mAb interactions. A, binding of His6-C2 to immobi-
lized 3E6 IgG (●) and G99 IgG (E). Bound His6-C2 was detected using the
Ni-NTA-alkaline phosphatase/pNPP system. B, ternary complex formation.
G99 IgG was incubated at various concentrations under the following condi-
tions: ELISA wells coated with 3E6 Fab, blocked, and then coated with C2 (●);
wells coated with 3E6 Fab and blocked (E); and wells blocked and then incu-
bated with C2 domain only (f). Bound G99 IgG was detected using goat
anti-mouse IgG-alkaline phosphatase. Error bars represent the mean  S.D. of
three to six independent measurements.
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ab initio molecular envelope (Fig. 7C). Previous studies had
localized theG99 epitope to Lys2227 of the fVIII C2 domain (22).
With this region of the C2 domain docked to the hypervariable
region of one Fab model, the opposing Fab fragment for anti-
body 3E6 was docked in accordance with the ab initiomolecu-
lar envelope for the ternary complex. In the resultingmodel, the
epitope for antibody G99 is centered upon the Pro2221–Trp2229
loop. By contrast, themodeled epitope for antibody 3E6, on the
opposing exposed face of the C2 domain, was inferred to
include loops Arg2209–Ser2216 and Leu2178–Asp2187.
To substantiate the proposed 3E6 epitope, we were able to
generate a soluble C2mutant (K2183A), which we analyzed via
ELISA for 3E6 and G99 IgG binding (Fig. 8). In agreement with
our SAXS-based model, the K2183A mutant exhibited signifi-
cantly decreased affinity for 3E6 (Fig. 8A), with a 20-fold
reduction in its apparentKd value (71 nM for K2183A compared
with 3.2 nM for WT C2). However, this K2183A mutation did
not have an observed effect onG99 IgG binding (Fig. 8B). These
FIGURE 5. Merged SAXS scattering curves. Scattering curves for each complex were background-corrected and merged for three different protein concen-
trations and three different x-ray exposure times. A, fVIII C2 domain. B, 3E6 Fab. C, G99 Fab. D, C2–3E6 Fab binary complex. E, C2-G99 Fab binary complex.
F, C2–3E6 Fab-G99 Fab ternary complex.
TABLE 1
SAXS-derived structural parameters
Complex Rgrecip Rgreal I(0) Dmax
Å Å Å
C2 domain 16.6  0.053 16.52  0.011 80.3  0.052 50
3E6 Fab 27.3  0.174 27.31  0.045 288  0.36 95
G99 Fab 26.6  0.076 26.93  0.028 286  0.23 90
C2–3E6 30.2  0.132 31.86  0.043 340  0.41 115
C2-G99 31.6  0.137 32.34  0.058 315  0.43 120
C2–3E6-G99 47.8  0.649 48.85  0.154 491  1.5 170
FIGURE 6. SAXS-derived pairwise distance distributions. Pairwise distribu-
tions were calculated with Dmax values. Blue, fVIII C2 domain; green, 3E6 Fab;
yellow, G99 Fab; red, C2–3E6 Fab binary complex; purple, C2-G99 Fab binary
complex; black, C2–3E6 Fab-G99 Fab ternary complex.
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data support our ab initiomodel and our assignment of the 3E6
epitope. Additionally, it was observed previously that mAb 3E6
competes with murine antibody ESH4 for binding to fVIII,
which has been determined, using porcine/human fVIII hybrid
constructs, to interact with C2 domain residues, including
Lys2181–Met2199 and Thr2207–Val2243, regions that encompass
the vicinity of our proposed 3E6 epitope.3
DISCUSSION
For 30% of hemophilia A patients, therapeutic infusions of
fVIII result in the development of anti-fVIII inhibitor antibod-
ies, which are the major impediment to effective therapy, espe-
cially for patients that showpoor response to immune tolerance
induction therapy. To develop more effective therapies for
hemophilia A, a more thorough understanding of fVIII-anti-
body interactions is crucial. In this work, we used the emergent
SAXS technique coupled with biochemical characterization to
investigate complexes formed between the human fVIII C2
domain and Fab fragments from two anti-human C2 inhibitor
mAbs, 3E6 andG99, derived from hemophilia Amice that were
infused with human fVIII. Plasma derived from human hemo-
philia A patients has been shown to harbor inhibitor antibodies
that competewith thesemAbs for binding toC2, indicating that
human inhibitor antibodies can recognize equivalent epitopes
on the C2 domain (32). Therefore, analysis of the interaction
between these murine mAbs and the human C2 domain can
likely be directly applicable to the understanding of the human
immune response to fVIII.
We sought to further establish the specific interactions
betweenmAbs 3E6 and G99 with the isolated fVIII C2 domain.
Three lines of biochemical evidence presented herein con-
firmed and extended the prior competition ELISA analysis of
fVIII interactions with mAbs 3E6 and G99. Results from bind-
ing assays employing purifiedHis6-C2 immobilized onNi-NTA
resin (Figs. 1 and 2), size exclusion chromatography analysis
(Fig. 3), and ELISA experiments (Fig. 4) indicate that 3E6 and
G99 target the C2 domain and, furthermore, can simultane-
ously bind to C2 to form a stable ternary complex. On the basis
of these results, we were able to characterize a C2-specific ter-
nary complex with two Fab fragments, which was essential for
the interpretation of SAXS data.
Preliminary analysis of SAXS data provided additional cor-
roborating evidence for the formation of stable C2–3E6,
C2-G99, and ternary complexes. First, analysis of the linearity
of Guinier plots derived from scattering intensity profiles of all
complexes indicates the absence of any significant aggregation,
in support of the proposition that the apparent shift in size
exclusion chromatography retention volumes is due to com-
FIGURE 7. Ab initio-derived solution structures and rigid body modeling. Molecular envelopes were generated with 50 independent GASBOR ab initio
structure calculations that were class-averaged with DAMAVER. Surfaces were calculated from bead models with Situs and displayed with Chimera.
A, superposition of the ternary envelope (gray mesh) with molecular envelopes of the C2 domain (magenta), 3E6 Fab (violet), and G99 Fab (cyan). B, superpo-
sition of the ternary envelope (gray mesh) with molecular envelopes of the C2–3E6 Fab binary complex (violet) and the C2-G99 Fab binary complex (cyan; the
overlap represents the fVIII C2 domain location). C, rigid body modeling of known structural components into the molecular envelope of the C2–3E6 Fab-G99
Fab ternary complex. Magenta, C2 domain; cyan, 3E6 Fab; yellow, G99 Fab.
FIGURE 8. ELISA of K2183A-mAb interactions. A, His6-K2183A binding to
immobilized 3E6 IgG (E) compared with His6-WT C2 binding (●). B, His6-
K2183A binding to immobilized G99 IgG (E) compared with His6-WT C2 bind-
ing (●). For clarity, the fitted saturation binding curve for K2183A-G99 bind-
ing in B is shown as a dashed line. Error bars represent the mean  S.D. of at
least three independent measurements.
Solution Structure of a fVIII-Inhibitor Antibody Complex




























plex formation as opposed to being attributed to nonspecific
aggregation. Calculated Rg values, derived from the pairwise
distribution function of all analyzed components, also agree
with the formation of C2–3E6/C2-G99 binary and C2–3E6-
G99 ternary complexes (Table 1).
Upon calculation of SAXS-based molecular envelope struc-
tures of the C2–3E6/C2-G99 binary and C2–3E6-G99 ternary
complexes, multiple insightful morphological details could be
discerned. Previously determined x-ray crystal structures of the
C2 domain, as well as a canonical Fab fragment lacking com-
plementarity-determining region loops, were readily modeled
into the molecular envelopes. Interestingly, the ternary com-
plex forms an elongated, moderately bent structure, with C2 at
its central point and wherein each Fab fragment recognizes a
distinct opposing face of theC2 domain. There appears to be no
overlap between bound Fab fragments, in support of the exis-
tence of such interactions existing in vivo without any steric
clashing between Fab fragments. Curiously, the proposed
membrane-binding hydrophobic loops of the bound C2
domain appear not to be directly involved in binding interac-
tions with either Fab fragment. This is in contrast to the previ-
ously determined structure of C2 bound to the classical inhib-
itor BOC211, derived from a hemophilia A patient and inwhich
the C2 membrane-binding region is fully enveloped by the Fab
fragment (37). It is possible thatmAb 3E6 binds proximal to the
membrane association surface of C2 and blocks membrane
binding via steric interactions arising from the peripheral IgG
structure, especially considering that a Fab fragment composes
only 33% of the full-length bound inhibitor antibody. How-
ever, preliminary analyses of fVIII inhibition behavior using a
one-stage clotting assay, comparing the Fab and whole IgG
forms of 3E6, showed that the 3E6 Fab fragment exhibits essen-
tially identical inhibition kinetics towhole IgG (Fig. 9A). There-
fore, further explorations into the mechanism of fVIII inhibi-
tion by classical type I inhibitor antibodies is warranted.
Determination of the epitopes for both mAbs 3E6 and G99,
combined with previous analysis of modes of inhibition by
these antibodies,may provide further insight into the regions of
binding of the fVIII C2 domain to PS and vWF, as well as the
proteases that activate fVIII, thrombin, and fXa. The proposed
epitope for mAb 3E6 suggests that the Ala2209–Ser2216 and
Leu2178–Asp2187 loops may contribute to PS and/or vWF bind-
ing. The G99 epitope suggests that thrombin and/or fXa binds
to the opposing face, which likely includes the Pro2221–Trp2229
loop. However, initial functional comparison of fVIII inhibitory
activity by G99 Fab and IgG showed that G99 Fab reduced fVIII
activity by only 40% compared with 80% by whole G99 IgG
(Fig. 9B). The dependence of fVIII inhibition activity on the
presence of the full IgG molecule suggests that this particular
epitope may not represent a binding site for thrombin or fXa
per se, but that the presence of the large full IgG may sterically
inhibit the interaction of these proteases with other proximal
interaction sites outside, but adjacent to, the C2 domain. The
implications of this variability in fVIII inhibition are currently
being examined further.
The interaction of C2 with classical inhibitors has been well
studied both biochemically and, in the case of the human-de-
rived mAb BO2C11, structurally (37). However, the SAXS-de-
rived molecular models presented here provide the first low
resolution glimpse of the binding of a non-classical type II
inhibitor to C2, as well as an additional binding mode for a
classical type I inhibitor. To our knowledge, this is the first
example of the use of SAXS to identify antibody epitopes at the
level of specific residues. Additionally, this is the first direct
structural evidence of multiple Fab fragments binding simulta-
neously to the C2 domain. These observations help expand the
understanding of the complex fVIII immune response andmay
assist in the development of more robust strategies for over-
coming the formulation of inhibitors. Elaboration of these
results with high resolution x-ray crystallographic mapping of
epitopes could lead to the design of recombinant fVIII variants
that display reduced immunogenicity. Future efforts will be
directed toward unambiguously determining whether these
mAbs exhibit cooperative behavior, investigating their mecha-
FIGURE 9. Bethesda assays for inhibition of fVIII activity in plasma. Pooled normal human plasma was successively diluted with IgG or Fab, and one-stage
coagulation activity was measured. A, inhibition of fVIII activity by 3E6 whole IgG (E) and 3E6 Fab (●). B, inhibition of fVIII activity by G99 whole IgG (E) and G99
Fab (●). 100% activity corresponds to the coagulation activity of pooled normal human plasma.
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nism of inhibition, and determining a high resolution x-ray
crystal structure of the C2–3E6-G99 ternary complex.
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